SAN DIEGO - Maravai LifeSciences, Inc. (NASDAQ: MRVI), a $796 million market cap company known for supplying life science reagents and services, has announced the acquisition of intellectual property ...

圣地亚哥 - 市值7.96亿美元的生命科学试剂和服务供应商Maravai LifeSciences, Inc. (NASDAQ: MRVI)宣布收购Molecular Assemblies, Inc.的知识产权和资产。根据 InvestingPro 数据，该公司保持强劲的流动性，流动比率为10.74，尽管面临近期挑战，过去十二个月收入下降34%。此次收购将增强Maravai子公司TriLink ...

Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Gearing Up to Initiate Phase 3 Ovarian Cancer Trial Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial of ...

Northwestern Medicine scientists have uncovered new details explaining how poxviruses manipulate host cells to enhance their ...

The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, ...

In trials at University College London Hospitals (UCLH), an ASO is being used to target the mutated gene that results in the ...

The bill's sponsor said that restriction was “an error,” and that she intends to change it if it were to move forward in the ...

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

研究团队发现，细胞在暴露于紫外线后首先响应的是RNA损伤，而这正是触发细胞死亡和皮肤炎症的原因。当ZAK基因被去除后，这些反应也随之消失。为此他们培育了一种缺乏ZAK基因的基因编辑小鼠。与正常小鼠相比，这些小鼠在暴露于紫外线后的头几个小时里，皮肤炎症显著减轻。这意味着ZAK在皮肤对紫外线诱导损伤的响应中发挥着关键作用。

Right now, we actually have no plans to move forward; it’s ready to go if we decide,” company spokeswoman said.

Most people associate sunburns with DNA damage -- it's what we've been taught in textbooks and by dermatologists for years.